1. Home
  2. NERV vs MBRX Comparison

NERV vs MBRX Comparison

Compare NERV & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NERV
  • MBRX
  • Stock Information
  • Founded
  • NERV 2007
  • MBRX 2015
  • Country
  • NERV United States
  • MBRX United States
  • Employees
  • NERV N/A
  • MBRX N/A
  • Industry
  • NERV Biotechnology: Pharmaceutical Preparations
  • MBRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NERV Health Care
  • MBRX Health Care
  • Exchange
  • NERV Nasdaq
  • MBRX Nasdaq
  • Market Cap
  • NERV 12.4M
  • MBRX 14.7M
  • IPO Year
  • NERV 2014
  • MBRX 2016
  • Fundamental
  • Price
  • NERV $1.84
  • MBRX $0.67
  • Analyst Decision
  • NERV Hold
  • MBRX Strong Buy
  • Analyst Count
  • NERV 1
  • MBRX 2
  • Target Price
  • NERV $5.00
  • MBRX $6.00
  • AVG Volume (30 Days)
  • NERV 15.2K
  • MBRX 1.0M
  • Earning Date
  • NERV 08-05-2025
  • MBRX 05-13-2025
  • Dividend Yield
  • NERV N/A
  • MBRX N/A
  • EPS Growth
  • NERV N/A
  • MBRX N/A
  • EPS
  • NERV 0.83
  • MBRX N/A
  • Revenue
  • NERV N/A
  • MBRX N/A
  • Revenue This Year
  • NERV N/A
  • MBRX N/A
  • Revenue Next Year
  • NERV N/A
  • MBRX N/A
  • P/E Ratio
  • NERV $2.23
  • MBRX N/A
  • Revenue Growth
  • NERV N/A
  • MBRX N/A
  • 52 Week Low
  • NERV $1.15
  • MBRX $0.40
  • 52 Week High
  • NERV $3.69
  • MBRX $4.90
  • Technical
  • Relative Strength Index (RSI)
  • NERV 65.83
  • MBRX 29.72
  • Support Level
  • NERV $1.75
  • MBRX $0.62
  • Resistance Level
  • NERV $1.90
  • MBRX $0.93
  • Average True Range (ATR)
  • NERV 0.12
  • MBRX 0.07
  • MACD
  • NERV 0.04
  • MBRX -0.03
  • Stochastic Oscillator
  • NERV 90.00
  • MBRX 14.06

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Share on Social Networks: